Inês Martins, PhD, managing science editor —

Inês holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, Inês won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.

Articles by Inês Martins

Galapagos, e-therapeutics Partner to Identify Compounds to Treat Fibrotic Diseases

Galapagos and e-therapeutics are partnering to investigate mechanisms involved in idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions and to select potential therapeutic candidates. The collaboration will combine Galapagos’ extensive knowledge on IPF and fibrosis with e-therapeutics’ Network-driven Drug Discovery (NDD) platform for examining disease mechanisms…

Algernon Gets Nod to Launch Phase 2 IPF Trial of NP-120 in Australia

Algernon Pharmaceuticals received the first ethics approval for its Phase 2 clinical trial in Australia evaluating its repurposed compound NP-120 (ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and associated chronic cough. Royal Brisbane and Women’s Hospital‘s Human Research Ethics Committee has approved two sites — the Cairns…

Software Detects ‘Molecular Signatures’ in Development of Lung and Liver Fibrosis

A collaborative research effort identified new pathways involved in fibrosis using a software tool known as “Regeneration Intelligence,” which evaluated perturbations in several signaling pathways in lung and liver fibrosis, and in glaucoma. The research, leading to two studies, was conducted by Insilico Medicine working with scientists at Atlas Regeneration, Vision Genomics, and Howard University. The…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums